Medical College of Wisconsin Cancer Center

Recent papers from Medical College of Wisconsin Cancer Center

1. Circulating tumor DNA in body fluids for molecular characterization of cancers beyond tissue and bloodiScience · 2026
2. Immune Checkpoint Inhibitors in Metastatic Renal Cell Carcinoma With Sarcomatoid Dedifferentiation: A Multicenter Retrospective StudyJournal of the National Comprehensive Cancer Network · 2026
3. Mitochondrial genetic variation as a novel predictor of graft-versus-host disease after stem-cell transplantation in myelodysplastic neoplasmsJournal of Hematology & Oncology · 2026
4. Germline Genomic and DNA Methylation Differences Between MGUS and Multiple Myeloma Among Patients of African AncestryCells · 2026
5. Molecular therapy matching score correlates with clinical outcomes: a system for navigating cancer complexitynpj Genomic Medicine · 2026
6. Neighborhood Contemporary Redlining and Racial Mortgage Lending Bias and Cardiovascular Outcomes in Women With Breast CancerJournal of the American Heart Association · 2026
7. Long-Term Outcomes of a Statewide Initiative to Reduce Margin Re-Excisions After LumpectomyJAMA Surgery · 2026
8. Macrophage source influences peritoneal persistence and immune cell dynamics in assays of reverse cholesterol transportJournal of Lipid Research · 2026
9. Characteristics of Gender-Diverse Patients With Breast CancerJAMA Network Open · 2026
10. IL-1-mediated inflammation promotes metastatic dissemination and resistance to EGFR-targeted therapynpj Precision Oncology · 2026
11. Living Guidelines for Tumor-Agnostic Therapies: A Pathway to Next-Generation Cancer TreatmentJCO Precision Oncology · 2026
12. Experiences and Challenges of Sexual and Gender Minority Patients Undergoing Breast Cancer TreatmentThe American Journal of Surgery · 2026
13. Fine Mapping of MHC Region Identifies Novel Susceptibility Loci in Multiple Myeloma When Comparing With Its Precursor Monoclonal Gammopathy of Unknown SignificanceHLA · 2026
14. Novel Genomic Biomarkers Improve Post–Hematopoietic Cell Transplantation Relapse Risk Stratification for Patients With Myelodysplastic SyndromesJCO Precision Oncology · 2026
15. Artificial intelligence approach to estimating trial feasibility with OncoLLM.Journal of Clinical Oncology · 2026
16. Inducible T‐Cell Co‐Stimulator ( ICOS ) and ICOS Ligand: Dealing With a Two‐Faced Cancer Immunoregulatory SystemCancer Medicine · 2025
17. Autoimmune HLA alleles and neoantigens predict myelodysplastic syndrome outcomes after allogeneic HSCT: A CIBMTR analysisiScience · 2025
18. CA turns 75: Looking at the future but never forgetting the rootsCA A Cancer Journal for Clinicians · 2025
19. 23Molecular residual disease (MRD) guided adjuvant ThErapy in renal cell carcinoma (RCC) -MRD GATE RCCThe Oncologist · 2025
20. Abstract B083: Defining a molecular basis and therapeutic approach for KEAP1-NRF2 mediated resistance to KRAS inhibition in KRAS-mutant pancreatic ductal adenocarcinomaCancer Research · 2025